| Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology W Van Rheenen, RAA Van Der Spek, MK Bakker, JJFA Van Vugt, PJ Hop, ... Nature genetics 53 (12), 1636-1648, 2021 | 407 | 2021 |
| Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis S Witzel, A Maier, R Steinbach, J Grosskreutz, JC Koch, A Sarikidi, S Petri, ... JAMA neurology 79 (2), 121-130, 2022 | 152 | 2022 |
| Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy A Pechmann, M Behrens, K Dörnbrack, A Tassoni, S Stein, S Vogt, ... Brain 146 (2), 668-677, 2023 | 46 | 2023 |
| Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen E Jochmann, R Steinbach, T Jochmann, HY Chung, A Rödiger, ... Therapeutic advances in neurological disorders 13, 1756286420907803, 2020 | 42 | 2020 |
| Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis M Dreger, R Steinbach, M Otto, MR Turner, J Grosskreutz Journal of Neurology, Neurosurgery & Psychiatry 93 (4), 422-435, 2022 | 38 | 2022 |
| Cerebrospinal fluid neurofilament light chain (NFL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model M Dreger, R Steinbach, N Gaur, K Metzner, B Stubendorff, OW Witte, ... Frontiers in neuroscience 15, 651651, 2021 | 34 | 2021 |
| Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics J Thome, R Steinbach, J Grosskreutz, D Durstewitz, G Koppe Human brain mapping 43 (2), 681-699, 2022 | 30 | 2022 |
| Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis R Steinbach, M Batyrbekova, N Gaur, A Voss, B Stubendorff, TE Mayer, ... NeuroImage: Clinical 25, 102094, 2020 | 29 | 2020 |
| Remote digital assessment of amyotrophic lateral sclerosis functional rating scale–a multicenter observational study T Meyer, S Spittel, T Grehl, U Weyen, R Steinbach, D Kettemann, S Petri, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24 (3-4), 175-184, 2023 | 27 | 2023 |
| Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen T Meyer, A Maier, Z Uzelac, T Hagenacker, R Günther, O Schreiber‐Katz, ... European Journal of Neurology 28 (8), 2582-2595, 2021 | 26 | 2021 |
| Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography R Steinbach, K Loewe, J Kaufmann, J Machts, K Kollewe, S Petri, ... Journal of neurology 262, 2257-2270, 2015 | 25 | 2015 |
| Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model R Steinbach, N Gaur, A Roediger, TE Mayer, OW Witte, T Prell, ... Human Brain Mapping 42 (3), 737-752, 2021 | 23 | 2021 |
| Symptomatic pharmacotherapy in ALS: Data analysis from a platform-based medication management programme T Meyer, D Kettemann, A Maier, T Grehl, U Weyen, J Grosskreutz, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (7), 783-785, 2020 | 22 | 2020 |
| Clinical and genetic features of amyotrophic lateral sclerosis patients with C9orf72 mutations M Wiesenfarth, K Günther, K Müller, S Witzel, U Weiland, K Mayer, ... Brain Communications 5 (2), fcad087, 2023 | 21 | 2023 |
| Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis WP Ruf, M Boros, A Freischmidt, D Brenner, V Grozdanov, J de Meirelles, ... Brain Communications 5 (3), fcad152, 2023 | 19 | 2023 |
| Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis R Steinbach, T Prell, N Gaur, A Roediger, C Gaser, TE Mayer, OW Witte, ... NeuroImage: Clinical 30, 102674, 2021 | 19 | 2021 |
| Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data T Prell, N Gaur, R Steinbach, OW Witte, J Grosskreutz Health and Quality of Life Outcomes 18, 1-5, 2020 | 19 | 2020 |
| Cathepsin D as biomarker in cerebrospinal fluid of nusinersen‐treated patients with spinal muscular atrophy DC Schorling, H Kölbel, A Hentschel, A Pechmann, N Meyer, B Wirth, ... European Journal of Neurology 29 (7), 2084-2096, 2022 | 18 | 2022 |
| Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study R Günther, CD Wurster, S Brakemeier, A Osmanovic, O Schreiber-Katz, ... The Lancet Regional Health–Europe 39, 2024 | 16 | 2024 |
| Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model R Steinbach, T Prell, N Gaur, B Stubendorff, A Roediger, B Ilse, OW Witte, ... Journal of clinical medicine 9 (9), 2873, 2020 | 15 | 2020 |
